Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating reaffirmed by stock analysts at Mizuho in a research note issued to investors on Friday, January 5th. They presently have a $10.00 price objective on the stock. Mizuho’s price target would suggest a potential upside of 117.39% from the stock’s previous close.
VIVE has been the topic of a number of other reports. ValuEngine lowered shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Northland Securities initiated coverage on shares of Viveve Medical in a report on Friday, January 5th. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $10.00.
Viveve Medical (NASDAQ VIVE) opened at $4.60 on Friday. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. Viveve Medical has a 1 year low of $3.75 and a 1 year high of $11.16. The company has a market cap of $89.36, a P/E ratio of -2.14 and a beta of -0.67.
A number of large investors have recently made changes to their positions in VIVE. Schwab Charles Investment Management Inc. acquired a new stake in Viveve Medical during the 2nd quarter worth $189,000. Rhumbline Advisers acquired a new position in Viveve Medical in the second quarter valued at $110,000. Bank of New York Mellon Corp acquired a new position in Viveve Medical in the second quarter valued at $310,000. JPMorgan Chase & Co. acquired a new position in Viveve Medical in the second quarter valued at $151,000. Finally, Teachers Advisors LLC acquired a new position in Viveve Medical in the second quarter valued at $196,000. Hedge funds and other institutional investors own 66.89% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://baseballnewssource.com/markets/mizuho-reaffirms-buy-rating-for-viveve-medical-vive/1817547.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.